## Hodgkin and Non-Hodgkin Lymphoma Staging Form

### Clinical Extent of Disease Before Any Treatment

- **Primary Tumor (T)**
  - No T category exists for Hodgkin and Non-Hodgkin Lymphoma.

- **Regional Lymph Nodes (N)**
  - No N category exists for Hodgkin and Non-Hodgkin Lymphoma.

- **Distant Metastasis (M)**
  - No M category exists for Hodgkin and Non-Hodgkin Lymphoma.

### Stage Category Definitions

#### Clinical

- **Stage I**
  - Involvement of a single lymphatic site (i.e. nodal region, Waldeyer’s ring, thymus or spleen) (I); or localized involvement of a single extralymphatic organ or site in the absence of any lymph node involvement (IE) (rare in Hodgkin lymphoma).

- **Stage II**
  - Involvement of two or more lymph node regions on the same side of the diaphragm (II); or localized involvement of a single extralymphatic organ or site in association with regional lymph node involvement with or without involvement of other lymph node regions on the same side of the diaphragm (IIE). The number of regions involved may be indicated by a subscript, as in, for example, II_3.

- **Stage III**
  - Involvement of lymph node regions on both sides of the diaphragm (III), which also may be accompanied by extralymphatic extension in association with adjacent lymph node involvement (IIIE) or by involvement of the spleen (IIIS) or both (IIIE,S). Splenic involvement is designated by the letter S.

- **Stage IV**
  - Diffuse or disseminated involvement of one or more extralymphatic organs, with or without associated lymph node involvement; or isolated extralymphatic organ involvement in the absence of adjacent regional lymph node involvement, but in conjunction with disease in distant site(s). Stage IV includes any involvement of the liver or bone marrow, lungs (other than by direct extension from another site), or cerebrospinal fluid.

#### Pathologic Extent of Disease Through Completion of Definitive Surgery

#### Anatomic Stage • Prognostic Groups

<table>
<thead>
<tr>
<th>Group</th>
<th>Clinical</th>
</tr>
</thead>
</table>
| I     | Involvement of a single lymphatic site (i.e. nodal region, Waldeyer’s ring, thymus or spleen) (I); or localized involvement of a single extralymphatic organ or site in the absence of any lymph node involvement (IE) (rare in Hodgkin lymphoma).
| II    | Involvement of two or more lymph node regions on the same side of the diaphragm (II); or localized involvement of a single extralymphatic organ or site in association with regional lymph node involvement with or without involvement of other lymph node regions on the same side of the diaphragm (IIE). The number of regions involved may be indicated by a subscript, as in, for example, II_3.
| III   | Involvement of lymph node regions on both sides of the diaphragm (III), which also may be accompanied by extralymphatic extension in association with adjacent lymph node involvement (IIIE) or by involvement of the spleen (IIIS) or both (IIIE,S). Splenic involvement is designated by the letter S.
| IV    | Diffuse or disseminated involvement of one or more extralymphatic organs, with or without associated lymph node involvement; or isolated extralymphatic organ involvement in the absence of adjacent regional lymph node involvement, but in conjunction with disease in distant site(s). Stage IV includes any involvement of the liver or bone marrow, lungs (other than by direct extension from another site), or cerebrospinal fluid.

#### Pathologic

- **Stage I**
  - Involvement of a single lymphatic site (i.e. nodal region, Waldeyer’s ring, thymus or spleen) (I); or localized involvement of a single extralymphatic organ or site in the absence of any lymph node involvement (IE) (rare in Hodgkin lymphoma).

- **Stage II**
  - Involvement of two or more lymph node regions on the same side of the diaphragm (II); or localized involvement of a single extralymphatic organ or site in association with regional lymph node involvement with or without involvement of other lymph node regions on the same side of the diaphragm (IIE). The number of regions involved may be indicated by a subscript, as in, for example, II_3.

- **Stage III**
  - Involvement of lymph node regions on both sides of the diaphragm (III), which also may be accompanied by extralymphatic extension in association with adjacent lymph node involvement (IIIE) or by involvement of the spleen (IIIS) or both (IIIE,S). Splenic involvement is designated by the letter S.

- **Stage IV**
  - Diffuse or disseminated involvement of one or more extralymphatic organs, with or without associated lymph node involvement; or isolated extralymphatic organ involvement in the absence of adjacent regional lymph node involvement, but in conjunction with disease in distant site(s). Stage IV includes any involvement of the liver or bone marrow, lungs (other than by direct extension from another site), or cerebrospinal fluid.

#### Modifiers for Group:

- **E** Extranodal
- **S** Spleen

#### A & B Classification (Symptoms)

- **A** Asymptomatic
- **B** Symptoms: fevers, night sweats, weight loss

- **Stage unknown**

### Hospital Name/Address

### Patient Name/Information

(continued on next page)
HODGKIN AND NON-HODGKIN LYMPHOMA STAGING FORM

PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)

REQUIRED FOR STAGING: None

CLINICALLY SIGNIFICANT:
- Associated with HIV/AIDS
- Symptoms at diagnosis (B symptoms)
- International Prognostic Index (IPI) score
- Follicular Lymphoma Prognostic Index (FLIPI) score
- International Prognostic Score (IPS)

Histologic Grade (G) (also known as overall grade)

- 2 grade system
- 3 grade system
- 4 grade system
- No 2, 3, or 4 grade system is available

Adapted Descriptors

Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been combined into Lymph-Vascular Invasion (LVI) for collection by cancer registrars. The College of American Pathologists’ (CAP) Checklist should be used as the primary source. Other sources may be used in the absence of a Checklist. Priority is given to positive results.

- Lymph-Vascular Invasion Not Present (absent)/Not Identified
- Lymph-Vascular Invasion Present/Identified
- Not Applicable
- Unknown/Indeterminate

Residual Tumor (R)
The absence or presence of residual tumor after treatment. In some cases treated with surgery and/or with neoadjuvant therapy there will be residual tumor at the primary site after treatment because of incomplete resection or local and regional disease that extends beyond the limit of ability of resection.

- RX Presence of residual tumor cannot be assessed
- R0 No residual tumor
- R1 Microscopic residual tumor
- R2 Macroscopic residual tumor

General Notes:
For identification of special cases of TNM or pTNM classifications, the “m” suffix and “y,” “r,” and “a” prefixes are used. Although they do not affect the stage grouping, they indicate cases needing separate analysis.

m suffix indicates the presence of multiple primary tumors in a single site and is recorded in parentheses: pT(m)NM.

y prefix indicates those cases in which classification is performed during or following initial multimodality therapy. The cTNM or pTNM category is identified by a “y” prefix. The ycTNM or ypTNM categorizes the extent of tumor actually present at the time of that examination. The “y” categorization is not an estimate of tumor prior to multimodality therapy.

r prefix indicates a recurrent tumor when staged after a disease-free interval, and is identified by the “r” prefix: rTNM.

a prefix designates the stage determined at autopsy: aTNM.

Clinical stage was used in treatment planning (describe): ________________________________

National guidelines were used in treatment planning: □ NCCN □ Other (describe): ________________________________

Physician signature ________________________________ Date/Time ________________________________

HOSPITAL NAME/ADDRESS ________________________________ PATIENT NAME/INFORMATION ________________________________

(continued from previous page)
Indicate on diagram primary tumor and regional nodes involved.

**Lymph nodes above the diaphragm**
1. Waldeyer’s ring
2. Cervical, supraclavicular, occipital, and pre-auricular
3. Infracavicular
4. Axillary and pectoral
5. Mediastinal
6. Hilar
7. Epitrochlear and brachial

**Lymph nodes below the diaphragm**
8. Spleen
9. Mesenteric
10. Paraaortic
11. Iliac
12. Inguinal and femoral
13. Popliteal

| Hospital Name/Address | Patient Name/Information |
## Primary Cutaneous Lymphoma Staging Form

<table>
<thead>
<tr>
<th>Clinical</th>
<th>Stage Category Definitions</th>
<th>Pathologic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Extent of disease before any treatment</td>
<td>Extent of disease through completion of definitive surgery</td>
<td></td>
</tr>
</tbody>
</table>

### Primary Tumor (T) Skin

- **T1**
  - Primary tumor cannot be assessed
  - Limited patches*, papules, and/or plaques**covering <10% of the skin surface. May further stratify into T1a (patch only) vs T1b (plaque ± patch).
- **T2**
  - Patches, papules or plaques covering ≥10% of the skin surface. May further stratify into T2a (patch only) vs T2b (plaque ± patch).
- **T3**
  - One or more tumors***(≥1-cm diameter)
  - Confluence of erythema covering ≥80% body surface area

### Regional Lymph Nodes (N)

- **N0**
  - No clinically abnormal peripheral lymph nodes; biopsy not required
- **N1**
  - Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 1 or NCI LN0-2
  - Clone negative
  - Clone positive
- **N2**
  - Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 2 or NCI LN3
  - Clone negative
  - Clone positive
- **N3**
  - Clinically abnormal peripheral lymph nodes; histopathology Dutch grades 3-4 or NCI LN4; clone positive or negative

### Distant Metastasis (M) Visceral

- **M0**
  - No visceral organ involvement (no pathologic M0; use clinical M to complete stage group)

### Peripheral Blood Involvement (B)

- **B0**
  - Absence of significant blood involvement: ≤5% of peripheral blood lymphocytes are atypical (Sézary) cells^1
  - Clone negative
  - Clone positive
- **B1**
  - Low blood tumor burden: >5% of peripheral blood lymphocytes are atypical (Sézary) cells but does not meet the criteria of B2
  - Clone negative
  - Clone positive
- **B2**
  - High blood tumor burden: ≥1000/µL Sézary cells^2^ with positive clone

### Notes

- *For skin, patch indicates any size skin lesion without significant elevation or induration. Presence/absence of hypo- or hyperpigmentation, scale, crusting, and/or poikiloderma should be noted.
- **For skin, plaque indicates any size skin lesion that is elevated or indurated. Presence or absence of scale, crusting, and/or poikiloderma should be noted. Histologic features such as folliculotropism or large-cell transformation (>25% large cells), CD30+ or CD30-, and clinical features such as ulceration are important to document.
- ***For skin, tumor indicates at least one 1-cm diameter solid or nodular lesion

---

HOSPITAL NAME/ADDRESS | PATIENT NAME/INFORMATION

(continued on next page)
with evidence of depth and/or vertical growth. Note total number of lesions, 
total volume of lesions, largest size lesion, and region of body involved. Also 
note if histologic evidence of large-cell transformation has occurred. 
Phenotyping for CD30 is encouraged.

^For node, abnormal peripheral lymph node(s) indicates any palpable peripheral 
node that on physical examination is firm, irregular, clustered, fixed or 1.5 
cm or larger in diameter. Node groups examined on physical examination 
include cervical, supraclavicular, epitrochlear, axillary, and inguinal. Central 
nodes, which are not generally amenable to pathologic assessment, are not 
currently considered in the nodal classification unless used to establish N3 
histopathologically.

^^For viscera, spleen and liver may be diagnosed by imaging criteria.

^^^For blood, Sézary cells are defined as lymphocytes with hyperconvoluted 
cerebriform nuclei. If Sézary cells are not able to be used to determine tumor 
burden for B2, then one of the following modified ISCL criteria along with a 
positive clonal rearrangement of the TCR may be used instead: (1) 
expanded CD4+ or CD3+ cells with CD4/CD8 ratio of 10 or more, (2) 
expanded CD4+ cells with abnormal immunophenotype including loss of 
CD7 or CD26.

# A T-cell clone is defined by PCR or Southern blot analysis of the T-cell 
receptor gene.

## Anatomic Stage • Prognostic Groups

<table>
<thead>
<tr>
<th>Group</th>
<th>T</th>
<th>N</th>
<th>M</th>
<th>B</th>
</tr>
</thead>
<tbody>
<tr>
<td>IA</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0.1</td>
</tr>
<tr>
<td>IB</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>0.1</td>
</tr>
<tr>
<td>IIA</td>
<td>1.2</td>
<td>1.2</td>
<td>0</td>
<td>0.1</td>
</tr>
<tr>
<td>IIB</td>
<td>3</td>
<td>0-2</td>
<td>0</td>
<td>0.1</td>
</tr>
<tr>
<td>III</td>
<td>4</td>
<td>0-2</td>
<td>0</td>
<td>0.1</td>
</tr>
<tr>
<td>IIIA</td>
<td>4</td>
<td>0-2</td>
<td>0</td>
<td>0.1</td>
</tr>
<tr>
<td>IIIB</td>
<td>4</td>
<td>0-2</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>IVA1</td>
<td>1-4</td>
<td>0-2</td>
<td>0</td>
<td>0-2</td>
</tr>
<tr>
<td>IVA2</td>
<td>1-4</td>
<td>3</td>
<td>0</td>
<td>0-2</td>
</tr>
<tr>
<td>IVB</td>
<td>1-4</td>
<td>0-3</td>
<td>1</td>
<td>0-2</td>
</tr>
<tr>
<td>Stage unknown</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Group</th>
<th>T</th>
<th>N</th>
<th>M</th>
<th>B</th>
</tr>
</thead>
<tbody>
<tr>
<td>IA</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0.1</td>
</tr>
<tr>
<td>IB</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>0.1</td>
</tr>
<tr>
<td>IIA</td>
<td>1.2</td>
<td>1.2</td>
<td>0</td>
<td>0.1</td>
</tr>
<tr>
<td>IIB</td>
<td>3</td>
<td>0-2</td>
<td>0</td>
<td>0.1</td>
</tr>
<tr>
<td>III</td>
<td>4</td>
<td>0-2</td>
<td>0</td>
<td>0.1</td>
</tr>
<tr>
<td>IIIA</td>
<td>4</td>
<td>0-2</td>
<td>0</td>
<td>0.1</td>
</tr>
<tr>
<td>IIIB</td>
<td>4</td>
<td>0-2</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>IVA1</td>
<td>1-4</td>
<td>0-2</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>IVA2</td>
<td>1-4</td>
<td>3</td>
<td>0</td>
<td>0-2</td>
</tr>
<tr>
<td>IVB</td>
<td>1-4</td>
<td>0-3</td>
<td>1</td>
<td>0-2</td>
</tr>
<tr>
<td>Stage unknown</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Prognostic Factors (Site-Specific Factors)

**Mycosis Fungoides and Sézary only**

**Required for Staging:** Peripheral blood involvement: _________________

**Clinically Significant:** None

**General Notes:**

For identification of special cases of TNM or pTNM classifications, the "m" 
suffix and "y," "r," and "a" prefixes are used. Although they do not affect the 
stage grouping, they indicate cases needing separate analysis.

*m* suffix indicates the presence of 
multiple primary tumors in a single site and is recorded in parentheses: 
pT(m)NM.
### Histologic Grade (G) (also known as overall grade)

**Grading system**
- 2 grade system
- 3 grade system
- 4 grade system
- No 2, 3, or 4 grade system is available

**Grade**
- Grade I or 1
- Grade II or 2
- Grade III or 3
- Grade IV or 4

**General Notes (continued):**
- **y** prefix indicates those cases in which classification is performed during or following initial multimodality therapy. The cTNM or pTNM category is identified by a “y” prefix. The ycTNM or ypTNM categorizes the extent of tumor actually present at the time of that examination. The “y” categorization is not an estimate of tumor prior to multimodality therapy.
- **r** prefix indicates a recurrent tumor when staged after a disease-free interval, and is identified by the “r” prefix: rTNM.
- **a** prefix designates the stage determined at autopsy: aTNM.

### Additional Descriptors

**Lymphatic Vessel Invasion (L) and Venous Invasion (V)** have been combined into Lymph-Vascular Invasion (LVI) for collection by cancer registrars. The College of American Pathologists’ (CAP) Checklist should be used as the primary source. Other sources may be used in the absence of a Checklist. Priority is given to positive results.

- Lymph-Vascular Invasion Not Present (absent)/Not Identified
- Lymph-Vascular Invasion Present/Identified
- Not Applicable
- Unknown/Indeterminate

### Residual Tumor (R)

The absence or presence of residual tumor after treatment. In some cases treated with surgery and/or with neoadjuvant therapy there will be residual tumor at the primary site after treatment because of incomplete resection or local and regional disease that extends beyond the limit of ability of resection.

- RX Presence of residual tumor cannot be assessed
- R0 No residual tumor
- R1 Microscopic residual tumor
- R2 Macroscopic residual tumor

---

- Clinical stage was used in treatment planning (describe): 
- National guidelines were used in treatment planning  
  - NCCN
  - Other (describe): 

---

Physician signature

Date/Time

---

**Hospital Name/Address**

**Patient Name/Information**

(continued on next page)
Illustration
Indicate on diagram primary tumor and regional nodes involved.

Lymph nodes above the diaphragm
1. Waldeyer’s ring
2. Cervical, supraclavicular, occipital, and pre-auricular
3. Infraclavicular
4. Axillary and pectoral
5. Mediastinal
6. Hilar
7. Epitrochlear and brachial

Lymph nodes below the diaphragm
8. Spleen
9. Mesenteric
10. Paraaortic
11. Iliac
12. Inguinal and femoral
13. Popliteal

Hospital Name/Address

Patient Name/Information

(continued from previous page)